Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).
Evoke Pharma Stock Performance
Evoke Pharma stock opened at $4.39 on Wednesday. The company’s 50-day moving average is $5.15 and its 200-day moving average is $5.44. Evoke Pharma, Inc. has a fifty-two week low of $3.54 and a fifty-two week high of $17.40.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Evoke Pharma in a research note on Wednesday, November 20th. They set a “sell” rating on the stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- What is the S&P 500 and How It is Distinct from Other Indexes
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Are Penny Stocks a Good Fit for Your Portfolio?
- 2 Generic Drug Stocks Ready to Surge in 2025
- Stock Market Upgrades: What Are They?
- 3 Small-Cap Stocks That Are Ready to Rocket Higher
Want to see what other hedge funds are holding EVOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report).
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.